Seroprevalence of hepatitis C virus: The first population-based study from Iran

International Journal of Infectious Diseases

Volumn 14, Issue SUPPL. 3, 2010, Pages

  Merat, Shahin ^a   Rezvan, Houri ^b   Nouraie, Mehdi ^a,c   Jafari, Elham ^a   Abolghasemi, Hassan ^d   Radmard, Amir Reza ^a   Zaer rezaii, Hanieh ^a   Amini Kafiabad, Sedigheh ^b   Maghsudlu, Mahtab ^b   Pourshams, Akram ^a   Malekzadeh, Reza ^a   Esmaili, Saeed ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^c HOWARD UNIVERSITY   (United States)

^d BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatitis C; Iran; Prevalence

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOBLOTTING; INFECTION RISK; INTRAVENOUS DRUG ABUSE; IRAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; RURAL AREA; SEROPREVALENCE; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOBLOTTING; IRAN; MALE; MIDDLE AGED; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 77955490310     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.11.032     Document Type: Article

References (25)

1. Craxi A., Laffi G., Zignego A.L. Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med 2008, 29:85-95.
2. Butt A.A. Hepatitis C virus infection: the new global epidemic. Expert Rev Anti Infect Ther 2005, 3:241-249.
3. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
4. Rezvan H., Ahmadi J., Farhadi M., Tardyan S. A preliminary study of prevalence of HCV infection in healthy Iranian blood donors. Vox Sang 1994, 67:149.
5. Amini-Kafiabad S., Rezvan H., Abolghasemi H., Talebian A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. Transfusion 2009, 49:2214-2220.
6. Makhlough A., Jamshidi M., Mahdavi M.R. Hepatitis C prevalence studied by polymerase chain reaction and serological methods in haemodialysis patients in Mazandaran, Iran. Singapore Med J 2008, 49:921-923.
7. Alavian S.M., Adibi P., Zali M.R. Hepatitis C virus in Iran: epidemiology of an emerging infection. Arch Iran Med 2005, 8:84-90.
8. Zamani S., Ichikawa S., Nassirimanesh B., Vazirian M., Ichikawa K., Gouya M.M., et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 2007, 18:359-363.
9. Karimi M., Ghavanini A.A. Seroprevalence of HBsAg, anti-HCV, and anti-HIV among haemophiliac patients in Shiraz, Iran. Haematologia (Budap) 2001, 31:251-255.
10. Sharifi-Mood B., Eshghi P., Sanei-Moghaddam E., Hashemi M. Hepatitis B and C virus infections in patients with hemophilia in Zahedan, southeast Iran. Saudi Med J 2007, 28:1516-1519.
11. Mirmomen S., Alavian S.M., Hajarizadeh B., Kafaee J., Yektaparast B., Zahedi M.J., et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med 2006, 9:319-323.
12. Rezvan H., Abolghassemi H., Kafiabad S.A. Transfusion-transmitted infections among multitransfused patients in Iran: a review. Transfus Med 2007, 17:425-433.
13. Merat S., Rezvan H., Nouraie M., Jamali A., Assari S., Abolghasemi H., et al. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. Arch Iran Med 2009, 12:225-231.
14. Alavian S.M., Gholami B., Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: a case-control study. J Gastroenterol Hepatol 2002, 17:1092-1097.
15. Razzaghi E.M., Movaghar A.R., Green T.C., Khoshnood K. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J 2006, 3:12.
16. Ganji A., Nouraie M., Sadatsafavi M., Nasseri Moghaddam S., Malekzadeh R. [Digestive and liver diseases statistics in Iran, 2000-2004] (in Persian). Govaresh 2006, 11:33-38.
17. Pourshams A., Malekzadeh R., Monavvari A., Akbari M.R., Mohamadkhani A., Yarahmadi S., et al. Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors. J Gastroenterol Hepatol 2005, 20:229-233.
18. Samimi-Rad K., Nategh R., Malekzadeh R., Norder H., Magnius L. Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol 2004, 74:246-252.
19. Keyvani H., Alizadeh A.H., Alavian S.M., Ranjbar M., Hatami S. Distribution frequency of hepatitis C virus genotypes in 2231 patients in Iran. Hepatol Res 2007, 37:101-103.
20. Malekzadeh R., Dehpour A.R. Report from Iran. Liver Int 2008, 28:1136-1139.
21. Malekzadeh R., Mohamadnejad M., Merat S., Pourshams A., Etemadi A. Obesity pandemic: an Iranian perspective. Arch Iran Med 2005, 8:1-7.
22. Jauncey M., Micallef J.M., Gilmour S., Amin J., White P.A., Rawlinson W., et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis 2004, 190:1270-1274.
23. Thein H.H., Yi Q., Dore G.J., Krahn M.D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008, 48:418-431.
24. Salomon J.A., Weinstein M.C., Hammitt J.K., Goldie S.J. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003, 290:228-237.
25. Buti M., Medina M., Casado M.A., Wong J.B., Fosbrook L., Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003, 17:687-694.